Fordyce spots are normal, harmless ectopic sebaceous (oil) glands visible as small, painless, yellow-white or skin-colored granular papules on the lips, inner cheeks, and genital mucosa. About 70 to 80 percent of adults have them. They are not contagious, not a sexually transmitted infection, and not a disease — they are normal anatomy. Removal is optional, purely cosmetic, and every available method is off-label, supported only by small case series with no randomized clinical trials, and carries real scarring and post-inflammatory hyperpigmentation (PIH) risk, especially in darker skin tones.
If you have noticed tiny yellowish bumps on your lips or inside your mouth that will not pop no matter what you try, you are almost certainly looking at Fordyce spots — and the most important thing to know is that they are not a sign of illness, infection, or any transmissible condition.
What Are Fordyce Spots, and Are They Contagious or an STD?
Fordyce spots (also called Fordyce granules or Fordyce glands) are ectopic sebaceous glands — the same oil-producing glands found in hair-bearing skin throughout the body — that sit in the mucosal or semi-mucosal tissue of the lips, oral cavity, and genitals without an associated hair follicle. Because there is no follicle channel, the sebum they produce has no exit pathway, making the gland itself visible as a small, raised, yellowish papule.
Key Clinical Facts
- Prevalence: About 80 percent of adults have Fordyce spots (DermNet); the Cleveland Clinic estimates 70 to 80 percent.
- Sex distribution: Males develop them roughly twice as often as females. In a clinicopathologic series of 16 biopsy-confirmed patients, 11 were male and 5 were female (Lee et al. 2012).
- Onset: Present from birth but become larger and more visible beginning at puberty, as rising androgen levels enlarge sebaceous glands.
- Histology: Biopsy shows mature sebaceous glands with sebaceous lobules that are mostly not associated with a hair follicle — the defining feature that separates Fordyce spots from normal follicle-associated sebaceous glands (Lee et al. 2012).
- Not an infection: Fordyce spots are ectopic oil glands — they contain no microbial agent. They cannot be transmitted through kissing, sexual contact, or any form of physical touch. They are not herpes, not HPV, not any sexually transmitted infection.
Common Locations
| Location | Appearance |
|---|---|
| Vermilion border of the lips | Small pale-yellow papules along the lip line; often most noticeable on the upper lip |
| Buccal mucosa (inner cheeks) | Clusters of granular yellow-white papules |
| Retromolar area / palate | Less common; small papules on the oral mucosa |
| Penile shaft / foreskin | Clusters of pale papules, often confused with pearly penile papules |
| Vulvar / labial mucosa | Less frequently noticed; small pale papules on the labia minora |
Important Accuracy Note
There is no dedicated StatPearls article for Fordyce spots. NBK537065, sometimes cited in this context, is actually titled "Physiology, Edema" and covers edema pathophysiology. NBK545207 covers Fox-Fordyce disease, which is a completely different condition — an apocrine miliaria affecting the axillae and groin, not sebaceous glands on mucosal tissue. Articles that cite a "Fordyce spots StatPearls" reference are citing the wrong source.
Do Fordyce Spots Go Away on Their Own, or Do They Need Removal?
Fordyce spots are lifelong. They do not resolve spontaneously once visible, and there is no medical reason to treat them. They are benign, they do not become malignant, and they cause no functional impairment.
Removal is considered only when the appearance causes cosmetic distress. Because Fordyce spots are normal anatomy, this is a personal cosmetic decision — not a medical one. Any provider recommending removal should frame it clearly as an elective, off-label procedure.
Can I Pop or Squeeze Fordyce Spots?
No. Unlike a whitehead or a closed comedone, a Fordyce spot has no pore opening (ostium) to the skin surface. There is nothing to express. Attempting to squeeze, pick, or lance them at home risks tissue damage, secondary bacterial infection, scarring, and post-inflammatory hyperpigmentation — the same principle as with milia, which also cannot and should not be popped. The key difference: milia are superficial keratin cysts that can be de-roofed by a single-pass sterile needle extraction; Fordyce spots are deeper ectopic glands with no follicle or pore, so extraction fails and destructive ablation methods are needed.
Fordyce Spots Removal: CO2 Laser vs Electrocautery vs Micro-punch vs Retinoids
Every available removal method is off-label. No device or drug is FDA-cleared or FDA-approved specifically for Fordyce spots. CO2 lasers used for Fordyce treatment are legally marketed general soft-tissue ablation devices cleared for broader indications — not for Fordyce spots by name (FDA 510(k) database). The same is true for electrocautery devices.
The entire evidence base consists of small case series and case reports. No randomized controlled trial has ever been conducted for any Fordyce spot treatment.
Removal Comparison Table
| Method | Evidence Level | How It Works | Key Results | Healing Time | Recurrence Risk |
|---|---|---|---|---|---|
| CO2 laser | Case series (2–3 patients) | Superpulsed or pinhole CO2 ablation vaporizes the gland | Complete re-epithelialization at 2 weeks, no side effects (Ocampo-Candiani et al. 2003, 2 patients); no recurrence at 4 months (Bhingradia et al. 2024, 3 patients) | 5–21 days | Low in small series, but long-term data are limited |
| Electrocautery / electrodesiccation | Expert recommendation, no published Fordyce-specific series | Electrical current destroys the gland through thermal coagulation | Widely used in clinical practice but no published patient-level outcome data specific to Fordyce | 3–5 days | Unknown; anecdotally moderate |
| Micro-punch excision | Case series (23 patients) | A 1 mm micro-punch biopsy removes each granule individually under local anesthesia | Very satisfactory cosmetic results; no recurrence over 12–84 months (median 51.3 months) (Pallua and Stromps 2013) | Up to 1 month | Lowest reported recurrence in any published series |
| Topical retinoids | Expert recommendation; variable response | Adapalene, tretinoin, or oral isotretinoin increase epidermal turnover to flatten or reduce visibility | Gradual reduction in some patients over 4–8 weeks; the only published isotretinoin data (Mutizwa and Berk 2014, 2 patients) shows dichotomous, often non-durable response — 1 of 2 patients relapsed within about a month | 2–6 weeks (ongoing use) | High; effect reverses on discontinuation |
| Cryotherapy | Expert recommendation; limited data | Liquid nitrogen destroys the gland through freezing | Anecdotally used; limited published data | About 3 days | Unknown |
What the Evidence Actually Shows
The strongest removal study by sample size is the Pallua and Stromps (2013) micro-punch series: 23 patients treated under local anesthesia with a 1 mm disposable biopsy punch removing each Fordyce granule individually. The cosmetic outcome was rated "very satisfactory" by both patients and operators, with zero recurrence over a median follow-up of 51.3 months (range 12–84 months). This study is almost never surfaced in consumer-facing search results.
The CO2 laser evidence rests on the seminal Ocampo-Candiani et al. (2003) series of 2 patients treated with superpulsed CO2 laser, showing complete re-epithelialization at 2 weeks with no reported side effects, and the more recent Bhingradia et al. (2024) pinhole CO2 series of 3 patients with no recurrence at 4 months.
Isotretinoin response is dichotomous and often not durable. In the only published case (Mutizwa and Berk 2014), two patients were treated: one showed sustained clearing, the other relapsed within approximately one month of stopping isotretinoin. This single observation should not be used to set expectations for patients.
How Much Does Fordyce Spot Removal Cost, and Does Insurance Cover It?
Because Fordyce spots are normal anatomy and removal is cosmetic, health insurance plans classify treatment as an elective cosmetic procedure and do not cover it.
| Cost Factor | Typical Range |
|---|---|
| Per-session cost | Roughly $200–$600, up to $1,000+ depending on extent and modality |
| Number of sessions | Varies by extent; many patients need 1–3 sessions for laser/electrocautery, 1 session for micro-punch |
| Insurance | Not covered; classified as cosmetic |
| Consultation fee | Often separate; $100–$250 |
Cost figures are from clinic and physician Q&A secondary sources and vary widely by geography and provider. They are not peer-reviewed or standardized.
Fordyce Spots in Skin of Color: PIH and Scarring Risk
Any ablative or destructive removal method — CO2 laser, electrocautery, cryotherapy, micro-punch — involves deliberate tissue injury. In individuals with Fitzpatrick skin types IV–VI, tissue injury from ablative procedures carries a well-established risk of post-inflammatory hyperpigmentation (PIH) that can persist for months to years after treatment and may be more cosmetically distressing than the Fordyce spots themselves.
Key Considerations
- No Fordyce-specific PIH study exists. The PIH risk for Fordyce removal in skin of color is a reasoned extrapolation from the broader ablative-procedure literature, not a Fordyce-specific finding. This should be discussed openly during the consent conversation.
- Same PIH-after-ablative-removal principle that shapes DPN removal decisions in skin of color applies here: the benefit of removing a benign, harmless lesion must be weighed against the risk of creating a more noticeable pigment change.
- Micro-punch may offer a lower PIH profile than CO2 laser or electrocautery because the tissue injury is more controlled and confined, but no head-to-head comparison exists.
- Test spots before treating a visible area are prudent. Treating one or two spots in a less conspicuous location and assessing healing and pigment response over 4–6 weeks before treating the lip or visible facial areas can reduce the risk of widespread PIH.
How Do I Tell Fordyce Spots Apart from Other Bumps?
Several benign conditions produce small papules on the face, lips, or genitals. Misidentification drives unnecessary anxiety — and occasionally unnecessary treatment.
Differential Diagnosis Table
| Condition | Location | Appearance | Key Difference from Fordyce Spots |
|---|---|---|---|
| Fordyce spots | Lips, inner cheeks, genital mucosa | Tiny, yellow-white, granular, 1–3 mm papules in clusters | Ectopic sebaceous glands without a hair follicle; on mucosa |
| Sebaceous hyperplasia | Face (forehead, nose, cheeks) | Yellow, dome-shaped papules with a central dell (indentation) | On sun-exposed facial skin, associated with a hair follicle, central dell present; carries a basal cell carcinoma differential |
| Milia | Periorbital skin, eyelids, cheeks, nose | Pearly white, hard, dome-shaped, 1–2 mm cysts | Superficial keratin cysts under intact stratum corneum; treatable by simple de-roofing; no follicle involvement |
| Pearly penile papules | Penile corona (circumferential) | Tiny, uniform, dome-shaped, skin-colored papules arranged in rows | Fibroangiomas of the corona; not sebaceous, not on mucosa; arranged in regular rows around the glans |
| Xanthelasma | Eyelids, periorbital | Flat or slightly raised, yellow, plaque-like deposits | Lipid-laden macrophage plaques that signal cardiovascular risk and may warrant a lipid panel; not sebaceous |
| Syringoma | Lower eyelids, periorbital | Skin-colored to slightly yellow, firm papules | Eccrine sweat-duct tumors; different tissue origin; syringoma and Fordyce spots share CO2 and electrocautery as removal modalities but differ in location and biology |
| Herpes simplex (cold sores) | Lips, perioral, genital | Grouped vesicles on an erythematous base; painful, crusting | Viral; episodic; vesicles (not papules); painful; Fordyce spots are painless, persistent, and never vesicular |
Fordyce spots are the mucosal, follicle-free cousin of facial sebaceous hyperplasia. The distinction matters: sebaceous hyperplasia sits on sun-exposed facial skin with a central dell and an associated hair follicle and carries a basal cell carcinoma look-alike concern, while Fordyce spots sit on mucosa, have no follicle, no dell, and no malignant differential.
Is There an FDA-Approved Device or Drug Specifically for Fordyce Spots?
No. There is no device FDA-cleared specifically for Fordyce spot removal, and there is no drug FDA-approved for Fordyce spots. CO2 lasers, electrocautery devices, and cryotherapy equipment are cleared for general soft-tissue ablation or destruction — their use on Fordyce spots is off-label application of a legally marketed device. Topical retinoids (adapalene, tretinoin) and oral isotretinoin are approved for acne; their use on Fordyce spots is off-label.
This off-label status does not make the procedures illegal — off-label use of cleared devices is standard in dermatology and aesthetic medicine — but it means that no manufacturer has submitted efficacy or safety data specific to Fordyce spots to the FDA, and the patient should understand this during the informed consent discussion.
Removal Decision Framework: Should You Treat, and How?
Because every Fordyce treatment is off-label with limited evidence, the decision to treat should follow a structured evaluation rather than defaulting to whatever the clinic offers.
Step 1: Confirm the Diagnosis
Before any treatment, a clinician should confirm that the lesions are Fordyce spots and not sebaceous hyperplasia (which has a basal cell carcinoma differential), milia (which can be de-roofed easily), or a condition requiring medical treatment. This is typically a clinical diagnosis that does not require biopsy.
Step 2: Assess Cosmetic Impact vs Treatment Risk
Key questions for the patient and provider:
- How much distress do the spots cause? If the spots are noticed only on close inspection and cause minimal concern, the risk-benefit ratio favors observation.
- What is the skin type? In Fitzpatrick IV–VI skin, ablative treatment carries PIH risk that may produce a worse cosmetic outcome than the original spots.
- What is the location? Lip vermilion and genital mucosa are more visible and more cosmetically sensitive, but also more prone to scarring complications in these delicate tissue areas.
- What is the patient's tolerance for recurrence? No treatment guarantees permanent clearance. Micro-punch has the best published recurrence data (0 of 23 patients over median 51.3 months), but all other modalities carry meaningful recurrence risk.
Step 3: Match the Modality to the Clinical Scenario
| Clinical Scenario | Best-Fit Modality | Rationale |
|---|---|---|
| Small number of spots, high cosmetic concern, lighter skin | CO2 laser (superpulsed or pinhole) | Quick, established technique, low recurrence in small series, acceptable healing |
| Large number of spots, genital location, concerns about scarring | Micro-punch excision | Best published recurrence data; controlled tissue removal; longer healing |
| Patient prefers non-procedural approach | Topical retinoid (adapalene or tretinoin) | Low-risk, gradual; effect is partial, reverses on discontinuation |
| Active inflammation or follicular irritation around spots | Observation + reassurance | Inflammation may indicate a different condition or recent manipulation; delay treatment until resolved |
| Skin of color (Fitzpatrick IV–VI) | Any modality with test-spot protocol first | All ablative methods carry PIH risk; test 1–2 spots in less visible area and assess healing over 4–6 weeks |
Location-Specific Considerations
Lip Vermilion
The lip vermilion is the most common reason patients seek treatment. Fordyce spots on the lips are highly visible in social settings and selfies, and the thin mucosal tissue of the vermilion heals differently from keratinized facial skin. Providers should use the lowest effective energy settings for laser or electrocautery to minimize thermal spread to surrounding tissue. Lip swelling for 3 to 7 days post-procedure is typical.
Buccal Mucosa (Inner Cheeks)
Fordyce spots on the buccal mucosa are usually less cosmetically distressing because they are not visible externally. Treatment is rarely indicated. If patients are anxious about the spots, the most useful intervention is reassurance that buccal Fordyce spots are a normal anatomical finding in the vast majority of adults.
Genital Mucosa
Genital Fordyce spots are a frequent source of STD anxiety. The clinical priority is reassurance: these are not herpes, not HPV, and not any infection. If a patient has been told by a partner or online that the spots "look like an STD," providing a clear explanation of the ectopic-gland mechanism and the 70–80 percent population prevalence is typically more helpful than offering removal. Treatment of genital Fordyce spots carries additional consent considerations around genital tissue sensitivity, healing time, and sexual activity abstinence during recovery.
The Evidence Gap: What We Still Do Not Know
Fordyce spots occupy an unusual position in dermatology: they are extremely common, completely benign, and yet the treatment evidence is remarkably thin. Some honest knowledge gaps worth noting:
- No head-to-head comparison exists between any two removal modalities. The "best" method is unknown because no study has compared CO2 laser, electrocautery, micro-punch, and retinoids against each other.
- No long-term scarring outcome data exists beyond the Pallua micro-punch series (84 months maximum follow-up). How treated tissue looks and feels 5 to 10 years later is unreported.
- No PIH-specific data exists for Fordyce treatment in skin of color. The PIH risk is extrapolated from the broader ablative-procedure literature.
- No cost-effectiveness study has compared the incremental benefit of treatment versus living with the spots. The clinical default — observation and reassurance — is free.
- No study has measured patient satisfaction or quality-of-life impact in a controlled fashion. We do not know how much distress Fordyce spots cause compared to other benign conditions.
These gaps do not mean treatment is wrong — they mean that patients should understand they are making a cosmetic decision with case-series-level evidence, not a medical decision with clinical-trial support.
When to See a Provider
See a dermatologist if:
- You are unsure whether the bumps are Fordyce spots, milia, sebaceous hyperplasia, pearly penile papules, or something else — a clinical examination can distinguish them.
- The lesions are painful, rapidly changing, crusting, or vesicular — these features suggest a different diagnosis.
- The cosmetic distress warrants discussing removal options, risks, cost, and realistic expectations.
- You are considering treatment in skin of color and want to assess PIH risk with a test spot before proceeding.
Ask your provider: "What is your evidence that this removal method works for Fordyce spots specifically, and what is the risk of PIH or scarring on my skin type?"
Frequently Asked Questions
Can I use over-the-counter Fordyce spot remover products?
Over-the-counter "Fordyce spot remover" products (typically topical formulations containing acids, retinoids, or plant extracts) are marketed online but are not regulated as drugs or devices by the FDA. No published evidence supports their efficacy for Fordyce spots specifically. If the cosmetic concern warrants treatment, a dermatologist-guided approach with a known modality and a realistic expectation conversation is safer.
Do Fordyce spots get worse with age?
Fordyce spots may become more prominent with age as sebaceous glands enlarge. They may also become more noticeable during periods of hormonal change. They do not become dangerous or transform into a different condition.
Are Fordyce spots the same as Fox-Fordyce disease?
No. Fox-Fordyce disease (also called apocrine miliaria) is a completely different condition — an intensely pruritic, papular eruption of the apocrine gland areas (axillae, areolae, inguinal region) caused by apocrine duct obstruction. It is not related to ectopic sebaceous glands. The shared "Fordyce" name causes confusion, but the conditions differ in anatomy, mechanism, presentation, and treatment.
Can laser treatment cause permanent scarring on the lips?
Yes — any ablative procedure on the lip vermilion carries a scarring risk, though in small published series (Ocampo-Candiani 2003, 2 patients; Bhingradia 2024, 3 patients) no clinically significant scarring was reported. The risk increases with deeper ablation, repeat treatments, and in darker skin tones where PIH can compound the cosmetic concern. Test spots and conservative energy settings mitigate this risk.
If I do nothing, are Fordyce spots harmful in any way?
No. Fordyce spots are normal anatomy present in the majority of adults. They do not become malignant, do not obstruct gland function, do not cause pain, and are not associated with any systemic disease. The only indication for treatment is patient-driven cosmetic preference. Doing nothing is the medically appropriate default.
Sources
- DermNet — Fordyce spots — https://dermnetnz.org/topics/fordyce-spots
- Cleveland Clinic — Fordyce Spots — https://my.clevelandclinic.org/health/diseases/24140-fordyce-spots
- Ocampo-Candiani J, et al. Treatment of Fordyce spots with CO2 laser. Dermatol Surg. 2003;29(8):869-871 — https://pubmed.ncbi.nlm.nih.gov/12859392/
- Pallua N, Stromps JP. Micro-punch technique for treatment of Fordyce spots: a surgical approach for an unpleasant condition of the male genital. J Plast Reconstr Aesthet Surg. 2013;66(1):e8-e11 — https://pubmed.ncbi.nlm.nih.gov/23026471/
- Lee JH, et al. Clinicopathologic Manifestations of Patients with Fordyce's Spots. Ann Dermatol. 2012;24(1):103-106 — https://pmc.ncbi.nlm.nih.gov/articles/PMC3283840/
- Mutizwa MM, Berk DR. Dichotomous long-term response to isotretinoin in two patients with Fordyce spots. Pediatr Dermatol. 2014;31(1):73-75 — https://pubmed.ncbi.nlm.nih.gov/22486258/
- Bhingradia YM, et al. Treatment of Fordyce Spots with CO2 Laser: A Case Series of Three Patients. J Cutan Aesthet Surg. 2024;17(1):78-80 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11086941/
- FDA 510(k) Premarket Notification Database — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
